tiprankstipranks
Hangzhou Tigermed Consulting Co., Ltd. Class H (HK:3347)
:3347
Hong Kong Market
3347
Hangzhou Tigermed Consulting Co., Ltd. Class H
RESEARCH TOOLSreports
Want to see HK:3347 full AI Analyst Report?

Hangzhou Tigermed Consulting Co., Ltd. Class H (3347) Stock Forecast & Price Target

4 Followers
See the Price Targets and Ratings of:

3347 Analyst Ratings

Strong Buy
7Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Hangzhou
Tigermed Consulting Co., Ltd. Class H
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

3347 Stock 12 Month Forecast

Average Price Target

HK$55.20
▲(2.22% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Hangzhou Tigermed Consulting Co., Ltd. Class H in the last 3 months. The average price target is HK$55.20 with a high forecast of HK$61.40 and a low forecast of HK$48.00. The average price target represents a 2.22% change from the last price of HK$54.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"HK$25","62":"HK$62","34.25":"HK$34.3","43.5":"HK$43.5","52.75":"HK$52.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":61.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$61.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$55.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$48.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,34.25,43.5,52.75,62],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.16,41.793846153846154,43.427692307692304,45.06153846153846,46.69538461538461,48.32923076923077,49.96307692307692,51.596923076923076,53.230769230769226,54.864615384615384,56.49846153846154,58.13230769230769,59.76615384615384,{"y":61.4,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.16,41.316923076923075,42.473846153846154,43.63076923076923,44.7876923076923,45.94461538461538,47.10153846153846,48.25846153846154,49.41538461538462,50.57230769230769,51.72923076923077,52.886153846153846,54.043076923076924,{"y":55.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.16,40.76307692307692,41.36615384615384,41.96923076923077,42.57230769230769,43.175384615384615,43.778461538461535,44.38153846153846,44.98461538461538,45.58769230769231,46.19076923076923,46.793846153846154,47.39692307692307,{"y":48,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.535,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.247,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":38.25,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.9,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.08,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.76,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.54,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.3,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.54,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.75,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":45.98,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.98,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.16,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetHK$61.40Average Price TargetHK$55.20Lowest Price TargetHK$48.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of China Analyst forecast on HK:3347
Unknown Analyst
Bank of China
Not Ranked
Bank of China
HK$48
Buy
-11.11%
Downside
Reiterated
05/02/26
Bank of China Sticks to Its Buy Rating for Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1)
UBS Analyst forecast on HK:3347
Unknown Analyst
UBS
Not Ranked
UBS
HK$56.7→HK$59.9
Buy
10.93%
Upside
Reiterated
04/28/26
Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1) Receives a Buy from UBS
CLSA Analyst forecast on HK:3347
Unknown Analyst
CLSA
Not Ranked
CLSA
HK$56.1
Buy
3.89%
Upside
Reiterated
04/28/26
CLSA Sticks to Its Buy Rating for Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1)
Citic Securities Analyst forecast on HK:3347
Unknown Analyst
Citic Securities
Not Ranked
Citic Securities
HK$56
Buy
3.70%
Upside
Reiterated
04/21/26
Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1) Gets a Buy from Citic Securities
Bank of America Securities Analyst forecast on HK:3347
Unknown Analyst
Bank of America Securities
Not Ranked
Bank of America Securities
HK$50
Buy
-7.41%
Downside
Reiterated
03/31/26
Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1) Gets a Buy from Bank of America Securities
Jefferies Analyst forecast on HK:3347
David Shang
Jefferies
Jefferies
HK$55
Buy
1.85%
Upside
Reiterated
03/31/26
Jefferies Remains a Buy on Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1)
Goldman Sachs Analyst forecast on HK:3347
Chris Pan
Goldman Sachs
Goldman Sachs
HK$61.4
Buy
13.70%
Upside
Reiterated
03/30/26
Goldman Sachs Sticks to Their Buy Rating for Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1)
HSBC Analyst forecast on HK:3347
Linda Shu
HSBC
HSBC
HK$51.1→HK$54
Buy
0.00%
Upside
Reiterated
11/05/25
HSBC Sticks to Its Buy Rating for Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1)
J.P. Morgan Analyst forecast on HK:3347
Yang Huang
J.P. Morgan
J.P. Morgan
HK$37→HK$38
Sell
-29.63%
Downside
Reiterated
10/29/25
J.P. Morgan Sticks to Their Sell Rating for Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1)
CICC Analyst forecast on HK:3347
Unknown Analyst
CICC
Not Ranked
CICC
HK$57.5
Buy
6.48%
Upside
Reiterated
08/29/25
Citi Analyst forecast on HK:3347
Ruili Bian
Citi
Citi
HK$37→HK$73
Buy
35.19%
Upside
Reiterated
07/14/25
Citi Reaffirms Their Buy Rating on Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1)
Daiwa Analyst forecast on HK:3347
Unknown Analyst
Daiwa
Not Ranked
Daiwa
HK$38
Sell
-29.63%
Downside
Reiterated
06/12/25
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of China Analyst forecast on HK:3347
Unknown Analyst
Bank of China
Not Ranked
Bank of China
HK$48
Buy
-11.11%
Downside
Reiterated
05/02/26
Bank of China Sticks to Its Buy Rating for Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1)
UBS Analyst forecast on HK:3347
Unknown Analyst
UBS
Not Ranked
UBS
HK$56.7→HK$59.9
Buy
10.93%
Upside
Reiterated
04/28/26
Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1) Receives a Buy from UBS
CLSA Analyst forecast on HK:3347
Unknown Analyst
CLSA
Not Ranked
CLSA
HK$56.1
Buy
3.89%
Upside
Reiterated
04/28/26
CLSA Sticks to Its Buy Rating for Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1)
Citic Securities Analyst forecast on HK:3347
Unknown Analyst
Citic Securities
Not Ranked
Citic Securities
HK$56
Buy
3.70%
Upside
Reiterated
04/21/26
Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1) Gets a Buy from Citic Securities
Bank of America Securities Analyst forecast on HK:3347
Unknown Analyst
Bank of America Securities
Not Ranked
Bank of America Securities
HK$50
Buy
-7.41%
Downside
Reiterated
03/31/26
Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1) Gets a Buy from Bank of America Securities
Jefferies Analyst forecast on HK:3347
David Shang
Jefferies
Jefferies
HK$55
Buy
1.85%
Upside
Reiterated
03/31/26
Jefferies Remains a Buy on Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1)
Goldman Sachs Analyst forecast on HK:3347
Chris Pan
Goldman Sachs
Goldman Sachs
HK$61.4
Buy
13.70%
Upside
Reiterated
03/30/26
Goldman Sachs Sticks to Their Buy Rating for Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1)
HSBC Analyst forecast on HK:3347
Linda Shu
HSBC
HSBC
HK$51.1→HK$54
Buy
0.00%
Upside
Reiterated
11/05/25
HSBC Sticks to Its Buy Rating for Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1)
J.P. Morgan Analyst forecast on HK:3347
Yang Huang
J.P. Morgan
J.P. Morgan
HK$37→HK$38
Sell
-29.63%
Downside
Reiterated
10/29/25
J.P. Morgan Sticks to Their Sell Rating for Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1)
CICC Analyst forecast on HK:3347
Unknown Analyst
CICC
Not Ranked
CICC
HK$57.5
Buy
6.48%
Upside
Reiterated
08/29/25
Citi Analyst forecast on HK:3347
Ruili Bian
Citi
Citi
HK$37→HK$73
Buy
35.19%
Upside
Reiterated
07/14/25
Citi Reaffirms Their Buy Rating on Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1)
Daiwa Analyst forecast on HK:3347
Unknown Analyst
Daiwa
Not Ranked
Daiwa
HK$38
Sell
-29.63%
Downside
Reiterated
06/12/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Hangzhou Tigermed Consulting Co., Ltd. Class H

3 Months
xxx
Success Rate
2/3 ratings generated profit
67%
Average Return
+17.30%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +17.30% per trade.
1 Year
Chen ChenUBS
Success Rate
2/3 ratings generated profit
67%
Average Return
+8.67%
Copying Chen Chen's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +8.67% per trade.
2 Years
xxx
Success Rate
2/3 ratings generated profit
67%
Average Return
+4.87%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +4.87% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

3347 Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
1
0
1
1
1
Buy
1
0
3
6
7
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
2
0
4
7
8
In the current month, 3347 has received 8 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 3347 average Analyst price target in the past 3 months is 55.20.
Each month's total comprises the sum of three months' worth of ratings.

3347 Financial Forecast

3347 Earnings Forecast

Next quarter’s earnings estimate for 3347 is HK$0.38 with a range of HK$0.31 to HK$0.45. The previous quarter’s EPS was HK$0.07. 3347 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 3347 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 3347 is HK$0.38 with a range of HK$0.31 to HK$0.45. The previous quarter’s EPS was HK$0.07. 3347 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 3347 has Performed in-line its overall industry.

3347 Sales Forecast

Next quarter’s sales forecast for 3347 is HK$2.15B with a range of HK$2.15B to HK$2.15B. The previous quarter’s sales results were HK$2.03B. 3347 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 3347 has Performed in-line its overall industry.
Next quarter’s sales forecast for 3347 is HK$2.15B with a range of HK$2.15B to HK$2.15B. The previous quarter’s sales results were HK$2.03B. 3347 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 3347 has Performed in-line its overall industry.

3347 Stock Forecast FAQ

What is HK:3347’s average 12-month price target, according to analysts?
Based on analyst ratings, Hangzhou Tigermed Consulting Co., Ltd. Class H’s 12-month average price target is 55.20.
    What is HK:3347’s upside potential, based on the analysts’ average price target?
    Hangzhou Tigermed Consulting Co., Ltd. Class H has 2.22% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Hangzhou Tigermed Consulting Co., Ltd. Class H a Buy, Sell or Hold?
          Hangzhou Tigermed Consulting Co., Ltd. Class H has a consensus rating of Strong Buy, which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Hangzhou Tigermed Consulting Co., Ltd. Class H’s share price target?
            The average share price target for Hangzhou Tigermed Consulting Co., Ltd. Class H is 55.20. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is HK$61.40 ,and the lowest forecast is HK$48.00. The average share price target represents 2.22% Increase from the current price of HK$54.
              What do analysts say about Hangzhou Tigermed Consulting Co., Ltd. Class H?
              Hangzhou Tigermed Consulting Co., Ltd. Class H’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of Hangzhou Tigermed Consulting Co., Ltd. Class H?
                To buy shares of HK:3347, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.